Kyverna Therapeutics, Inc. Common Stock (KYTX) is a publicly traded Healthcare sector company. As of September 22, 2026, KYTX trades at $7.31 with a market cap of $440.94M and a P/E ratio of -1.95. KYTX moved +2.11% today. Year to date, KYTX is -24.26%; over the trailing twelve months it is +22.76%. Its 52-week range spans $1.78 to $13.67. Analyst consensus is strong buy with an average price target of $30.33. Rallies surfaces KYTX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks politician and congressional stock disclosures for KYTX, including purchases, sales, transaction dates, owners, and reported trade amounts when available.
| Metric | Value |
|---|---|
| Price | $7.31 |
| Market Cap | $440.94M |
| P/E Ratio | -1.95 |
| EPS | $-3.64 |
| Dividend Yield | 0.00% |
| 52-Week High | $13.67 |
| 52-Week Low | $1.78 |
| Volume | 254.06K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-161.31M |
| Gross Margin | 0.00% |
4 analysts cover KYTX: 0 strong buy, 4 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $30.33.